Research Abstract Template

Submissions must not exceed 300 words (excluding title & authors). The document **must not** be password protected or saved as read only as this may result in your abstract failing to upload successfully. Use Calibri 11 point type only. Please structure your submission using the subheadings below. If the abstract does not fit the headings, please put full abstract beneath introduction and we will remove the headings once submitted.

OVERLAPPING ADVERSE HEALTH OUTCOMES AMONG PEOPLE WHO INJECT DRUGS IN ENGLAND, WALES AND NORTHERN IRELAND, 2019-2020

Authors:

Edmundson C¹, Croxford S¹, Emanuel E¹, Njoroge J¹, Slater L¹, Hope V^{1,2}, Desai M¹

Background:

People who inject drugs (PWID) have increased risk of a wide range of negative health outcomes. We describe the burden and overlap of infections and overdose among PWID, alongside associated risk behaviours, to better understand their impact.

Methods:

We analysed data from the Unlinked Anonymous Monitoring Survey in England, Wales and Northern Ireland (EWNI). Participants self-completed a questionnaire and provided a biological sample tested for HIV, HBV and HCV. We included data for 2019/20 (first participations) from those who injected during the preceding year. We assessed prevalence of HIV, current HCV and HBV, overdose and/or a skin and soft tissue infection (SSTI) in the preceding year. PWID were grouped by the number of adverse health outcomes and behaviours compared through multivariable logistic regression, adjusting for age, gender and region, using Stata-15.

Results:

During 2019/20, 0.7% were HIV positive, 27% had chronic HCV and 0.3% current HBV; 38% reported a SSTI and 22% an overdose during the preceding year. Overall, 18% had \geq 2 adverse health outcomes. Compared to PWID with \leq 1, those with \geq 2 adverse outcomes had significantly greater odds of reporting high-risk behaviours: sharing injecting equipment (adjusted odds ratio: 1.65; 95% confidence interval: 1.28-2.14), stimulant (1.69; 1.26-2.27) or neck injection (2.16; 1.36-3.41) in the preceding month, ever imprisonment (1.37; 1.05-1.79), ever homelessness (1.68; 1.19-2.38), and multiple sexual partners in the preceding year (1.42; 1.08-1.86). Those with \geq 2 adverse outcomes had lower odds of reporting current drug treatment engagement (0.70; 0.54-0.91) but higher odds for needle and syringe programme (NSP) use during the preceding year (1.69; 1.15-2.47).

Conclusion:

A significant group of PWID in EWNI experience overlapping adverse health outcomes. Despite high engagement with NSP, people with overlapping adverse health outcomes are more likely to exhibit high-risk behaviours. Provision of holistic services is required to meet the multiple complex needs of this population.

Disclosure of Interest Statement:

No conflicts of interest.

Words: 300 not including the DOI statement. (300 word limit)

¹The UK Health Security Agency, London.

² Liverpool John Moores University, Liverpool.

Research Abstract Template

Submissions must not exceed 300 words (excluding title & authors). The document **must not** be password protected or saved as read only as this may result in your abstract failing to upload successfully. Use Calibri 11 point type only. Please structure your submission using the subheadings below. If the abstract does not fit the headings, please put full abstract beneath introduction and we will remove the headings once submitted.